Bodal Chemicals Ltd. Overview
Bodal Chemicals is an Ahmedabad-based, promoter-run chemical manufacturer that describes itself as India's largest integrated producer of dyestuffs and dye intermediates. Its model runs from sulphur-based basic chemicals through dye intermediates such as Vinyl Sulphone and H-Acid to finished reactive, acid and direct dyes, with roughly 40% of each upstream layer consumed captively. Since 2021 it has diversified through a chlor-alkali complex at Rajpura in Punjab, a TCCA water-treatment chemical business, and a greenfield benzene-derivatives site at Saykha in Gujarat. Consolidated revenue crossed Rs 2,000 crore in FY2026 for the first time since FY2022, and Q1 FY2027 delivered record quarterly revenue of about Rs 715 crore. The balance sheet remains the constraint: borrowings of Rs 813 crore, sub-investment-grade-adjacent ratings (IND BBB+ and IVR A-), return on equity near 4%, and no dividend since FY2023. The share price tripled in the year to October 2026.
What the company does. Bodal manufactures about 200 chemical products across five lines: basic (sulphur-based) chemicals, dye intermediates, dyestuffs, chlor-alkali products, and, more recently, benzene downstream derivatives and trichloroisocyanuric acid (TCCA). The Q1 FY2027 investor presentation gives total installed capacity of about 470,000 MTPA across eight manufacturing facilities in Gujarat, Punjab and Uttar Pradesh.
The company's own description. The FY2025-26 Annual Report presents the year as a pivotal chapter defined by strategic clarity, and identifies the commissioning of the Saykha greenfield facility as central to that progress. It describes Saykha as the company's entry into benzene derivatives (MCB, PNCB, ONCB, MNCB and DCB), opening pharmaceutical, agrochemical, pigment and polymer markets, and says the site uses German adiabatic nitration technology. The FY2024-25 Annual Report calls Bodal "India's largest integrated manufacturer of dyestuffs and dye intermediates".
Independent characterisation. Bodal is best understood as a mid-sized, vertically integrated commodity-to-semi-specialty chemical producer whose earnings are driven by spreads on a few benchmark molecules. Vinyl Sulphone and H-Acid prices set dye intermediate profitability. Caustic soda realisations (ECU) set chlor-alkali profitability. Sulphur prices pass through basic chemicals revenue. The "specialty" label applies to a minority of the portfolio (TCCA, some benzene derivatives, liquid dyes). The integration is real and lowers cost, but it does not insulate margins: consolidated operating margin fell from 16–18% in FY2015–FY2019 to 8–11% in FY2022–FY2026 (Screener.in, consolidated).
Revenue model. Revenue is almost entirely product sales, sold at spot or short-contract prices to industrial buyers and distributors. There is no subscription, licensing or service revenue of note. Minor other streams are trading by subsidiaries (India, China, Indonesia, Bangladesh), export incentives, and state incentive income (Rs 26.98 crore of Punjab SGST incentive recognised in FY2026).
Value chain position.
Customers and reach. Trade Brains (August 2026, citing company material) reports more than 600 customers served through 70+ distributors. The Q1 FY2027 presentation claims presence in 30+ countries. On a standalone basis exports were 21% of FY2026 sales, down from 25% in FY2025.
End-markets. Textiles dominate demand for dyestuffs and, indirectly, intermediates. Leather and paper are secondary. Chlor-alkali serves paper, textiles, soaps and alumina. Benzene derivatives and TCCA are the routes into pharmaceuticals, agrochemicals, pigments, polymers and water treatment.
Strategy
Stated themes (Annual Reports FY2025 and FY2026; results commentary). The company frames its strategy around integration, diversification beyond dyes, compliance-led manufacturing, and balance sheet repair. The FY2026 Annual Report title pairs "Excellence" with "Sustainability". Earlier (2022), Ankit Patel said the aim was to be among the top five Indian companies in benzene chemistry.
Medium-term financial guidance. Management guided FY2027 revenue of Rs 2,000–2,100 crore at a 12–13% EBITDA margin (Tijori Finance summary of the call). Q1 FY2027 revenue of Rs 715 crore annualises well above that range, while the 10.5% margin is below it. Either the revenue guidance is conservative or management expects raw-material-driven prices to ease. No guidance beyond FY2027 was found.
Sustainability commitments. The company cites zero liquid discharge at multiple sites, effluent treatment plants and multiple-effect evaporators, bluesign system partnership, and waste-heat power. Quantified emissions targets were not found.
Cost programmes. No named cost programme with a rupee target. The Vatva closure and working-capital reduction (net working capital days 124.9 to 104.8) are the tangible measures.
Products & Services
Product lists are from the Q3 FY2026 investor presentation (via Screener.in) and the company website. Pricing is market-linked and not disclosed for any product. Launch years are given only where disclosed.
Basic Chemicals (about 12 products; capacity 217,600 MTPA per Q1 FY2027 deck)
| Product | Description and use | Notes |
|---|---|---|
| Sulphuric Acid | Made from sulphur; feedstock for intermediates, fertilisers and detergents | Core of the integration chain |
| Oleum 23% | Fuming sulphuric acid for sulphonation | Captive and merchant |
| Oleum 65% | High-strength oleum for dye and pharma sulphonation | Captive and merchant |
| Sulphur Trioxide | Sulphonating agent | Liquid SO3 also planned at Saykha |
| Chlorosulphonic Acid | Key input for Vinyl Sulphone | Largely captive |
| Thionyl Chloride | Chlorinating agent for dyes, agro and pharma | 36,000 MTPA plant commissioned March 2019 at Unit VII |
| Sodium Bisulphate | By-product salt | Merchant |
| Acetanilide | Input for Vinyl Sulphone | Backward integration |
| Beta Naphthol | Naphthalene derivative for dyes and pigments | Merchant and captive |
| Para Nitro Aniline | Intermediate for azo dyes and pigments | Merchant and captive |
Dye Intermediates (about 25 products; capacity 38,400 MTPA)
| Product | Description and use | Notes |
|---|---|---|
| Vinyl Sulphone and derivatives | Reactive group for reactive dyes; Bodal's founding product | 6,000 MTPA line at the former SPS unit commercialised FY2023; price benchmark for the business |
| H-Acid | Coupling component for reactive and acid black/blue dyes | 3,000 MTPA at Kosi; second price benchmark |
| DASA | Diamino stilbene disulphonic acid; optical brighteners and direct dyes | — |
| F.C. Acid | Coupling component | — |
| Gamma Acid | Naphthalene-based coupling component | — |
| K-Acid | Used in reactive yellows | — |
| Sulpho Tobias Acid | Used in reactive reds | — |
| 4-NADPSA | Nitro amino diphenylamine sulphonic acid; acid dyes | — |
| 6-Nitro | Diazo component | — |
| MPDSA | Meta-phenylene diamine sulphonic acid | — |
| Meta Ureido Aniline | Reactive yellow and orange dyes | — |
| 1:2:4 Diazo | Diazo component for acid and chrome dyes | — |
| BDSA | Benzidine disulphonic acid; used in Reactive Yellow 84, Reactive Orange 84, Acid Red 97, Acid Yellow 42 | Company website |
Dyestuffs (about 175 products; about 35,000 MTPA powder plus 10,000 MTPA liquid per earlier decks)
| Product family | Description and target customer | Notes |
|---|---|---|
| Reactive Dyes | Cellulosic (cotton) dyeing; largest family | Sold to textile processors and distributors in India, Bangladesh, Turkey and others |
| Acid Dyes | Wool, silk, nylon and leather | — |
| Direct Dyes | Paper and cotton | — |
| Liquid Dyes | Paper and textile continuous processes | 10,000 MTPA; utilisation above 50% by August 2020 |
Chlor Alkali (about 6 products; Rajpura, Punjab; 99,000 MTPA caustic soda)
| Product | Description | Notes |
|---|---|---|
| Caustic Soda Lye | Membrane-cell caustic | 82,500 MTPA at acquisition, upgraded to 99,000 MTPA in FY2023 |
| Caustic Soda Flakes | Solid caustic | 33,000 MTPA flaking capacity (company website) |
| Chlorine | Co-product | Regional sales |
| Hydrogen | Co-product | — |
| Hydrochloric Acid | Chlorine derivative | — |
| Sodium Hypochlorite | Bleach and disinfectant | — |
| Stable Bleaching Powder | Water treatment | — |
Benzene Downstream (Saykha, Gujarat; 63,000 MTPA)
| Product | Description | Notes |
|---|---|---|
| MCB (Monochlorobenzene) | Chlorination of benzene; base for nitrochlorobenzenes | Commissioned in phases from December 2023 |
| PNCB (Para-nitrochlorobenzene) | Pharma (paracetamol chain), dyes, agro | Annual Report FY2026 cites continuous crystallisation technology |
| ONCB (Ortho-nitrochlorobenzene) | Pigment and agro intermediates | — |
| MNCB (Meta-nitrochlorobenzene) | Specialty intermediates | — |
| DCB (Dichlorobenzenes) | Polymers (PPS), agro | — |
Water Purification
| Product | Description | Notes |
|---|---|---|
| TCCA 90 | Trichloroisocyanuric acid, >90% available chlorine, moisture 0.5% max | 12,000 MTPA at Khambhat; zero-effluent plant; US EPA registration no. 99758-1 (company website) |
| SDIC 60% | Sodium dichloroisocyanurate | 2,400 MTPA shown as "upcoming" on the website |
Financial Narrative
All figures consolidated, Rs crore unless stated, from Screener.in's transcription of audited statements. EBITDA is operating profit plus other income. Company-reported "total revenue" includes other income and is slightly higher (FY2026: Rs 2,053.9 crore).
Income statement
Gross profit. Bodal does not publish a gross profit line, and third-party aggregates are inconsistent with each other, so gross profit is treated as not publicly disclosed in a comparable form.
Revenue CAGR. FY2022–FY2026 (4 years): -0.5%. FY2021–FY2026 (5 years, base Rs 1,226 crore): 10.4%. The five-year figure flatters because FY2021 was a pandemic trough.
Source conflicts. TipRanks shows FY2022 net income of about Rs 104 crore against Screener's Rs 99 crore, likely a difference in treatment of minority interest. The company's FY2026 release gives EBITDA of Rs 202.85 crore and PAT of Rs 47.83 crore, matching the table. MarketsMojo's Q4 FY2026 note cites "annual net profit of Rs 18 crore"; that is the FY2025 figure.
Commentary. Revenue peaked in FY2022 on post-pandemic restocking, fell 32% over two years as intermediate prices collapsed, and recovered to Rs 2,012 crore in FY2026. Profit did not follow. FY2026 EBITDA was below FY2022 despite Rs 600 crore more gross fixed assets, because Saykha added depreciation and interest before it added margin. Interest cost nearly tripled, from Rs 29 crore to Rs 79 crore. FY2026 earnings also leaned on Rs 35 crore of other income and Rs 26.98 crore of Punjab SGST incentive booked in revenue (company results note). Stripping both out, pre-tax profit would have been close to zero.
Quarterly trend (consolidated, Rs crore; Screener.in)
Two quarters in the middle of FY2026 had operating margins under 5%, cushioned by other income. Q4 FY2026 and Q1 FY2027 show a different level of earnings: about Rs 30 crore of quarterly profit. Trailing-twelve-month revenue is Rs 2,267 crore and profit Rs 68.7 crore.
Balance sheet
Cash and equivalents, the short-term versus long-term debt split, and goodwill and intangibles could not be extracted from the audited statements and are not estimated. Net debt above is back-calculated from the company's published ratio and implies cash of roughly Rs 38 crore in both years. Rating letters give partial debt composition: India Ratings rated term loans of Rs 507.4 crore and working-capital limits of Rs 510 crore in July 2025.
Commentary. Borrowings rose from Rs 454 crore in FY2021 to Rs 911 crore in FY2025 to fund Rajpura and Saykha, then fell by Rs 98 crore in FY2026, the first meaningful reduction in six years. Equity grew only Rs 105 crore in four years.
Cash flow
No buyback was found in the period.
Commentary. FY2022–FY2024 absorbed about Rs 700 crore of capex. FY2026 is the inflection: investing cash flow turned positive (asset disposals exceeded spending), and Rs 191 crore went to debt service and repayment.
Ratios
ROIC and the current ratio are not computed because the cash and current-liability detail was not available. On FY2026 figures, net debt to EBITDA is about 3.8x (derived). MarketsMojo cites debt to EBITDA of 5.49x on its own multi-year averaging.
Commentary. Returns have been below any reasonable cost of capital for four years. The one clear operating improvement is working capital: the cash conversion cycle shortened by 60 days since FY2022, mainly through inventory.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Location | Stake | Role |
|---|---|---|---|
Bodal Chemicals Ltd. (parent) | Gujarat, Punjab, Uttar Pradesh | — | All manufacturing |
Bodal Chemicals Trading Pvt. Ltd. (BCTPL) | Gujarat, India | 100% | Domestic trading; Q1 FY2027 sales Rs 6.52 crore |
Bodal Chemicals Trading (Shijiazhuang) Co., Ltd. | China | 100% | Trading; Q1 FY2027 sales Rs 1.09 crore (Rs 7.95 crore a year earlier) |
Sen-er Boya Kimya Tekstil Sanayi ve Ticaret A.S. | Turkey | 100% | Dyestuff manufacturing and distribution; hyperinflation accounting applies |
Senpa Dis Ticaret A.S. | Turkey | 100% (step-down) | Trading arm of Sen-er Boya |
Bodal Bangla Ltd. | Bangladesh | 100% | Market access to Bangladesh textile processors |
PT Bodal Chemicals Indonesia | Indonesia | 100% | Trading; Q1 FY2027 sales Rs 1.44 crore, loss-making |
Plutoeco Enviro Association | Gujarat, India | 25% (associate) | Not-for-profit environmental infrastructure company |
Division Overview
| Division | FY2026 |
|---|---|
Dye Intermediates (INR Cr) | 709.7 |
Dyestuffs (INR Cr) | 529.4 |
Chlor Alkali (INR Cr) | 338.7 |
Basic Chemicals (INR Cr) | 165.5 |
Others incl. benzene downstream, TCCA, trading, other income (INR Cr, derived) | 310.6 |
Total revenue (INR Cr) | 2,053.9 |
Division Overview — Dye Intermediates
| Division | FY2026 |
|---|---|
Dye Intermediates (% of total) | 34.6 |
Dyestuffs (% of total) | 25.8 |
Chlor Alkali (% of total) | 16.5 |
Basic Chemicals (% of total) | 8.1 |
Others (% of total, derived) | 15.1 |
Revenue by Segment
| Division | Q1 FY2026 | Q1 FY2027 |
|---|---|---|
Dye Intermediates (INR Cr) | 150.4 | 216.6 |
Dyestuffs (INR Cr) | 121.1 | 149.0 |
Basic Chemicals (INR Cr) | 44.4 | 83.9 |
Chlor Alkali (INR Cr) | 84.5 | 87.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 2,055 | 1,574 | 1,395 | 1,748 | 2,012 |
Operating expenses (INR Cr) | 1,835 | 1,441 | 1,284 | 1,578 | 1,844 |
Operating profit before other income (INR Cr) | 220 | 133 | 111 | 171 | 168 |
Other income (INR Cr) | -2 | 12 | 9 | -1 | 35 |
EBITDA (INR Cr, derived) | 218 | 145 | 120 | 170 | 203 |
Depreciation (INR Cr) | 47 | 53 | 60 | 69 | 70 |
Operating income / EBIT (INR Cr, derived) | 171 | 92 | 60 | 101 | 133 |
Interest (INR Cr) | 29 | 41 | 54 | 82 | 79 |
Pre-tax income (INR Cr) | 142 | 51 | 5 | 19 | 54 |
Net income (INR Cr) | 99 | 38 | 6 | 18 | 48 |
EPS basic and diluted (INR) | 8.51 | 3.03 | 0.51 | 1.47 | 3.80 |
Dividend per share (Rs, derived from payout ratio) | 0.80 | 0.10 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating margin before other income (%) | 10.7 | 8.4 | 8.0 | 9.8 | 8.3 |
EBITDA margin (%) | 10.6 | 9.2 | 8.6 | 9.7 | 10.1 |
EBIT margin (%) | 8.3 | 5.8 | 4.3 | 5.8 | 6.6 |
Net margin (%) | 4.8 | 2.4 | 0.4 | 1.0 | 2.4 |
Revenue growth YoY (%) | 67.6 | -23.4 | -11.4 | 25.3 | 15.1 |
Income Statement and Margin Analysis (%)
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|
Sales (INR Cr) | 454 | 480 | 490 | 588 | 709 |
Operating profit (INR Cr) | 48 | 23 | 22 | 69 | 69 |
Operating margin (%) | 10.0 | 4.8 | 4.5 | 12.0 | 10.0 |
Other income (INR Cr) | 4 | 20 | 15 | 3 | 6 |
Interest (INR Cr) | 22 | 20 | 19 | 18 | 19 |
Net profit (INR Cr) | 10 | 6 | 0 | 32 | 30 |
EPS (INR) | 0.76 | 0.48 | 0.02 | 2.55 | 2.41 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 2,113 | 2,120 | 2,281 | 2,339 | 2,336 |
Net fixed assets (INR Cr) | 817 | 967 | 1,314 | 1,301 | 1,239 |
Capital work in progress (INR Cr) | 70 | 193 | 68 | 61 | 67 |
Other assets incl. working capital and cash (INR Cr) | 1,227 | 960 | 886 | 977 | 1,031 |
Total borrowings (INR Cr) | 676 | 760 | 904 | 911 | 813 |
Other liabilities (INR Cr) | 385 | 283 | 294 | 324 | 366 |
Shareholders' equity (INR Cr) | 1,052 | 1,078 | 1,082 | 1,105 | 1,157 |
Returns & Leverage Ratios and Working Capital (Days)
| Metric | FY2025 | FY2026 |
|---|---|---|
Net debt to equity (x, company presentation) | 0.79 | 0.67 |
Net debt (INR Cr, derived from the ratio) | 873 | 775 |
Net working capital days (company presentation) | 124.9 | 104.8 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | -14 | 290 | 204 | 114 | 176 |
Investing cash flow (INR Cr) | -170 | -315 | -278 | -41 | 9 |
Financing cash flow (INR Cr) | 181 | 33 | 81 | -73 | -191 |
Free cash flow (INR Cr, Screener definition) | -170 | -29 | -29 | 69 | 180 |
Net capex (INR Cr, derived as OCF minus FCF) | 156 | 319 | 233 | 45 | -4 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, derived on average equity) | 9.8 | 3.6 | 0.6 | 1.6 | 4.2 |
ROA (%, derived) | 4.7 | 1.8 | 0.3 | 0.8 | 2.1 |
ROCE (%, Screener) | 12 | 5 | 3 | 6 | 6 |
Gross debt to equity (x, derived) | 0.64 | 0.71 | 0.84 | 0.82 | 0.70 |
Gross debt to EBITDA (x, derived) | 3.1 | 5.2 | 7.5 | 5.4 | 4.0 |
Interest coverage, EBIT / interest (x, derived) | 5.9 | 2.2 | 1.1 | 1.2 | 1.7 |
Asset turnover (x, derived) | 0.97 | 0.74 | 0.61 | 0.75 | 0.86 |
Debtor days | 105 | 97 | 100 | 83 | 80 |
Inventory days | 141 | 119 | 139 | 139 | 106 |
Payable days | 81 | 72 | 102 | 97 | 81 |
Cash conversion cycle (days) | 165 | 144 | 137 | 125 | 105 |
Revenue by Region (%)
| Region | FY2025 | FY2026 |
|---|---|---|
Domestic (% of standalone sales) | 75 | 79 |
Export (% of standalone sales) | 25 | 21 |
Revenue by Region
| Region | FY2025 | FY2026 |
|---|---|---|
Domestic (INR Cr, derived) | 1,300 | 1,590 |
Export (INR Cr, derived) | 433 | 423 |
Group Entities (Quarterly)
| Subsidiary | Q1 FY2026 sales (INR Cr) | Q1 FY2027 sales (INR Cr) | Comment |
|---|---|---|---|
Sen-er Boya (Turkey) | 4.6 (derived from 41% growth) | 6.48 | PAT Rs 2.15 crore against a loss a year earlier |
Bodal China (Shijiazhuang) | 7.95 | 1.09 | Sharp decline |
PT Bodal Indonesia | — | 1.44 | Loss-making |
BCTPL (India trading) | 2.46 | 6.52 | Growth |
“—” = not publicly disclosed.
Share Price & Returns
| Period | Return |
|---|---|
1 year | +202% |
3 years | +33% a year compounded (about +135% cumulative, derived) |
5 years | +8% a year compounded (about +47% cumulative, derived) |
10 years | +2% a year compounded |
52-week range | Rs 41.2 to Rs 208 |
Latest close | Rs 190 (1 October 2026) |
Valuation Multiples
| Multiple | Bodal (1 Oct 2026) | Basis |
|---|---|---|
P/E (TTM) | 34.8 | Screener.in |
P/B | 2.07 | Rs 190 / book value Rs 91.9 |
EV / EBITDA (TTM) | About 13.9 | Derived: EV about Rs 3,165 crore (market cap plus net debt about Rs 775 crore); TTM EBITDA about Rs 227 crore |
EV / Sales (TTM) | About 1.4 | Derived on TTM sales of Rs 2,267 crore |
Dividend yield | 0% | — |
Returns & Leverage Ratios (%) and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Dividend payout (% of profit) | 23 | 9 | 3 | 0 | 0 | 0 |
Dividend per share (Rs, derived) | 0.80 | 0.80 | 0.10 | 0 | 0 | 0 |
Analyst Ratings & Targets
| Date | Agency | Rating | Action |
|---|---|---|---|
| 2023 | India Ratings (Fitch group) | IND A / Negative; IND A1 | Downgraded from IND A+ / IND A1+ |
29–30 Dec 2023 | India Ratings | IND BBB+ / Negative; IND A2 | Downgraded; term loan Rs 639 crore, working capital Rs 556 crore |
8 Jul 2024 | India Ratings | IND BBB+ | — |
17–22 Jul 2025 | India Ratings | IND BBB+ / Stable; IND A2 | Outlook revised to Stable; term loan Rs 507.4 crore |
8 Dec 2025 | Infomerics | IVR A- / Stable; IVR A2+ | Assigned on Rs 1,127.53 crore, including proposed Rs 50 crore commercial paper |
Analyst Conclusions
Management guidance. FY2027 revenue of Rs 2,000–2,100 crore at 12–13% EBITDA margin; Saykha towards 70–80% utilisation; TCCA volume growth of 10–15%; about Rs 120 crore of annual debt repayment; no major capex for two years.
Consensus. No usable consensus exists. Trailing revenue is already Rs 2,267 crore, above the top of guidance.
Bull case
-
Earnings have reset. Two consecutive quarters of about Rs 30 crore profit imply Rs 120 crore annualised, 2.5 times FY2026.
-
Operating leverage on sunk capital. Rs 700 crore of FY2022–FY2024 capex is now producing revenue with no further spend planned; each Rs 100 crore of debt repaid adds roughly Rs 9–10 crore to pre-tax profit at current borrowing costs (derived from FY2026 interest and debt).
-
Protected and scarce positions. Sole Indian TCCA producer under a five-year duty; largest domestic intermediate producer as Indian compliance costs remove smaller rivals.
Bear case
-
The price has run ahead. At 34.8 times trailing earnings and 2.1 times book for a business earning 4% on equity, the valuation assumes a recovery not yet delivered. A promoter-group member sold in late September.
-
Margins are not improving. Q1 FY2027 EBITDA margin (10.5%) was below both the prior year and guidance. Revenue growth is largely price pass-through, which reverses when crude falls.
-
Earnings quality and leverage. FY2026 profit relied on other income and an uncollected incentive; interest cover is 1.7 times; ratings are BBB+/A-.
Catalysts and monitorables (next 12 months)
| Item | What to watch |
|---|---|
| Q2 FY2027 results (due November 2026) | Whether quarterly PAT holds near Rs 30 crore and margin reaches 12% |
| Saykha | Utilisation level, pharma approvals, first disclosed divisional profit |
| Debt | Borrowings below Rs 750 crore by March 2027 |
| Punjab SGST | Cash receipt of the Rs 26.98 crore accrual |
| Asset sales | Completion and proceeds for Unit I Vatva and Rajpura land |
| Ratings | India Ratings review; any upgrade to the A category |
| Shareholding | Further promoter-group sales; further accumulation by the 5% holder; any institutional entry |
| Dividend | Resumption would signal balance sheet confidence |
| Board | Succession for independent directors reaching ten years in 2027 |
Analyst verdict
Bodal Chemicals in October 2026 is two different stories depending on which quarter is read. On the five-year record it is a leveraged, low-return commodity chemical company that spent about Rs 700 crore diversifying at the top of a cycle, tripled its interest bill, and earned a cumulative Rs 209 crore over FY2022–FY2026 on more than Rs 1,000 crore of equity. On the last two quarters it is a recovering integrated producer with record revenue, falling debt, a finished capex programme and a tariff-protected niche.
Both readings are accurate. The operating recovery is real: volumes in dye intermediates rose 18% in Q1 FY2027, the working-capital cycle is 60 days shorter than in FY2022, and FY2026 produced Rs 180 crore of free cash flow. The investment case depends on whether Rs 30 crore of quarterly profit is a floor or a peak inflated by crude-linked pricing. The evidence does not yet settle that. EBITDA margin fell year on year in the record quarter, Saykha's benzene derivatives are still described by management as under competitive pressure, and FY2026 earnings needed incentive accruals and other income to look respectable.
The share price has not waited for the answer. A 202% gain, circuit-bound trading, no institutional holders and a promoter-group sale at the highs describe a stock driven by momentum more than by changed fundamentals. At Rs 190 the market capitalises Bodal at roughly 14 times trailing EBITDA, a multiple usually reserved for specialty chemical companies with mid-teens returns.
For a lender or counterparty, the direction is favourable: leverage is falling and the business is more diversified than at any time in its history. For an equity holder, the company must now deliver sustained 12–13% margins, visible Saykha profitability and continued debt reduction simply to justify the current price. The business is improving; the stock already assumes it has improved.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | On board since | Age | Background |
|---|---|---|---|---|
Suresh J. Patel | Chairman and Managing Director; promoter | 31 May 2005 (MD from 13 May 2009) | 70 | Founder; started the business in 1989. Re-appointed for three years in 2025 |
Bhavin S. Patel | Executive Director; promoter group | 31 May 2005 (whole-time from 1 Apr 2014 per MCA) | 45 | Son of the founder. Re-appointed for three years in 2025 |
Ankit S. Patel | Executive Director; promoter group | 2008 | 43 | Son of the founder; management's spokesperson on results; leads growth projects |
Rajarshi Ghosh | Director – Health, Safety and Environment (executive) | 26 May 2020 | 53 | HSE professional |
Nalin Kumar | Independent Director | 13 Feb 2017 | 57 | — |
Neha Sunil Huddar | Independent Director | 9 May 2017 | 65 | — |
Mayank Kulinchandra Mehta | Independent Director | 9 Feb 2021 | 68 | — |
Rohit B. Maloo | Independent Director | 11 Dec 2022 | — | — |
Mayur B. Padhya | Chief Financial Officer (not on board) | — | — | Long-serving CFO; leads earnings calls |
Ashutosh B. Bhatt | Company Secretary and Compliance Officer | — | — | Signs exchange filings |
Bansibhai M. Patel | President – Production and Technical; promoter group | — | — | Holds 0.03% |
“—” = not publicly disclosed.
Governance Overview
| Item | Position |
|---|---|
Chair / CEO separation | Not separated; the founder is Chairman and Managing Director |
Independence | 4 of 8 directors (50%), the regulatory minimum for an executive-chair board |
Family concentration | Three of four executive directors are father and two sons |
Committees | Audit, Nomination and Remuneration, Stakeholders' Relationship, CSR, Risk Management (the last includes the CMD, an Executive Director, the HSE director, an independent director, the CFO and the President – Production) |
Tenure watch | Two independent directors appointed in 2017 reach the ten-year limit in 2027 |
Pledges | Promoters declared no encumbrance on shares for FY2026 (filings of April and June 2026) |
Board & Management Changes
| Date | Change |
|---|---|
12 Aug 2025 | Board recommends re-appointment of the CMD and one Executive Director for three years; recommends B N P S and Associates LLP as auditor |
26 Sep 2025 | Shareholders approve at the 39th AGM |
25 Sep 2026 | 40th AGM; all resolutions passed |
Major Shareholders
| Holder | Category | Stake (%) | Source |
|---|---|---|---|
Suresh J. Patel | Promoter | 29.47 | Exchange shareholding pattern |
Bhavin S. Patel | Promoter group | 8.33 | Same |
Ankit S. Patel | Promoter group | 5.77 | Same |
Shakuntala J. Patel | Promoter group | 5.29 | Same |
Ashokkumar Giriraj Bansal | Public, non-promoter | 5.01 | SAST disclosure; bought 1,75,000 shares on 11 Sep 2026 to reach 63,05,000 |
Meena S. Patel | Promoter group | 4.15 | Shareholding pattern |
Ramesh D. Patel | Promoter group | About 3.8 | Sold 1,70,000 shares on 29 Sep 2026; holding fell to 47,75,880 |
Rakesh R. Patel | Promoter group | 0.04 | Shareholding pattern |
Bansi M. Patel | Promoter group | 0.03 | Shareholding pattern |
Competitive Landscape
Competitors by Segment
| Line | Named competitors |
|---|---|
Dye intermediates (Vinyl Sulphone, H-Acid) | Kiri Industries, Bhageria Industries, Shree Pushkar Chemicals & Fertilisers, Kutch Chemical Industries (unlisted) |
Dyestuffs | Kiri Industries, Atul Ltd., Jay Chemical Industries (unlisted), Colourtex (unlisted), Mahickra Chemicals; globally Zhejiang Longsheng, Zhejiang Runtu, Archroma, Huntsman-origin businesses |
Pigment and colour peers (listed comparables) | Sudarshan Chemical Industries, Sudarshan Colorants India, Asahi Songwon Colors, Ultramarine & Pigments, Poddar Pigments, Vidhi Specialty Food Ingredients |
Chlor-alkali | Primo Chemicals (formerly Punjab Alkalies), DCM Shriram, Gujarat Alkalies & Chemicals, Grasim Industries, Epigral |
Benzene derivatives | Aarti Industries (dominant in nitrochlorobenzenes), Kutch Chemical, Panoli Intermediates, Seya Industries |
Sulphuric acid and derivatives | Regional smelter and fertiliser acid producers; Aarti Industries |
TCCA | Chinese and Japanese exporters (now under duty); Bodal is described by Reuters as India's sole producer |
Peer Comparison FY2026
| Company | Market cap (INR Cr) | P/E (TTM) | P/B | ROE (%) |
|---|---|---|---|---|
Sudarshan Chemical Industries | 8,831 | 396.0 | 2.56 | 0.64 |
Kiri Industries | 2,768 | 0.50 (distorted by a one-off gain) | 0.43 | 86.48 |
Ultramarine & Pigments | 1,151 | 14.25 | 1.32 | 9.28 |
Sudarshan Colorants India | 926 | 19.39 | 1.63 | 7.81 |
Bhageria Industries | 913 | 13.25 | 1.53 | 7.76 |
Bodal Chemicals (6 Aug 2026) | 900 | 13.11 | 0.78 | 4.13 |
Asahi Songwon Colors | 446 | 12.79 | 1.64 | 6.91 |
Poddar Pigments | 265 | 17.97 | 0.76 | 4.20 |
Mahickra Chemicals | 252 | 48.93 | 3.77 | 7.71 |
Bodal Chemicals (1 Oct 2026) | 2,390 | 34.8 | 2.07 | About 4 |
Peer Comparison FY2026 — Revenue
| Measure | Bodal Chemicals | Kiri Industries | Sudarshan Chemical | Bhageria Industries |
|---|---|---|---|---|
Revenue (INR Cr) | 2,012 (FY2026) | About 950 (TTM, Value Research) | About 9,922 (TTM consolidated, Value Research) | — |
Revenue growth | +15% (FY2026) | — | Not comparable (acquisition-driven) | — |
Net margin | 2.4% (FY2026) | Distorted by one-off gain | 0.54% | — |
ROE | About 4% | 86.5% (one-off) | 0.64% | 7.76% |
Integration | Sulphur to dyes; chlor-alkali; benzene | Intermediates to dyes | Pigments, global | Intermediates, solar |
Recent Developments
--



